Bondil: Uses, Dosage & Side Effects
Alprostadil urethral suppository for the treatment and diagnosis of erectile dysfunction in adult men, delivered via a single-use applicator system
Bondil (alprostadil) is a prescription urethral suppository used to treat erectile dysfunction (ED) in adult men. It contains prostaglandin E1, which relaxes smooth muscle and increases blood flow to the penis, producing an erection within 5–10 minutes. Bondil is administered using a disposable applicator inserted into the urethra and is an effective second-line treatment when oral PDE5 inhibitors are not suitable or effective.
Quick Facts: Bondil (Alprostadil)
Key Takeaways
- Bondil contains alprostadil (prostaglandin E1), a vasodilator that produces erection by increasing penile blood flow when administered via the urethra.
- It is indicated for the treatment and diagnosis of erectile dysfunction in adult men aged 18 and older who may not respond to or tolerate oral ED medications.
- The maximum recommended dose is 1000 mcg per application, with no more than 2 doses in 24 hours and no more than 7 doses per week.
- Seek immediate medical attention if an erection lasts longer than 4 hours (priapism), as this can cause permanent damage to the erectile tissue.
- Bondil must be stored in a refrigerator (2–8°C) but the pack in use can be kept at room temperature (up to 30°C) for up to 14 days.
What Is Bondil and What Is It Used For?
Bondil contains the active substance alprostadil, a synthetic form of prostaglandin E1 (PGE1), a naturally occurring compound found throughout the body. When administered into the urethra, alprostadil is absorbed through the urethral mucosa into the surrounding corpus cavernosum — the spongy erectile tissue of the penis. There it relaxes smooth muscle cells and dilates the cavernosal arteries, leading to increased arterial inflow and reduced venous outflow. The net result is the engorgement of the penis with blood, producing an erection.
Bondil is indicated for the treatment and diagnosis of erectile dysfunction (ED) in adult men aged 18 years and older. Erectile dysfunction — the consistent inability to achieve or maintain an erection sufficient for satisfactory sexual intercourse — affects an estimated 150 million men worldwide, according to data from the World Health Organization. The prevalence increases significantly with age, affecting approximately 40% of men at age 40 and nearly 70% of men at age 70.
As a second-line therapy, Bondil is typically prescribed when first-line oral treatments such as phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) have proven ineffective, are contraindicated, or are poorly tolerated. It may also be used as a diagnostic tool to help evaluate the nature and severity of erectile dysfunction in a clinical setting.
The urethral route of administration offers a non-invasive alternative to intracavernosal injection therapy (such as Caverject), which also uses alprostadil but requires direct injection into the penis. Studies published in the Journal of Urology and the International Journal of Impotence Research have demonstrated that intraurethral alprostadil produces clinically meaningful erections in approximately 43–65% of men with erectile dysfunction of various etiologies, including vascular, neurogenic, psychogenic, and mixed causes.
It is important to note that alprostadil, the active ingredient in Bondil, may also be approved for other conditions not described in this article. Always follow the instructions of your prescribing physician and consult a healthcare professional if you have any questions about the use of this medication.
What Should You Know Before Taking Bondil?
Before starting treatment with Bondil, it is essential that your physician conducts a thorough medical evaluation. This should include a complete medical history, physical examination, and assessment of cardiovascular fitness for sexual activity. The European Association of Urology (EAU) guidelines emphasize that erectile dysfunction may be an early marker of underlying cardiovascular disease, and appropriate screening should be performed.
Contraindications
You should not use Bondil if any of the following apply:
- Allergy to alprostadil or any other ingredient in the product (macrogol/polyethylene glycol)
- Penile anatomical deformity such as severe curvature, angulation, or fibrosis, including Peyronie’s disease
- Urethral infection (urethritis) or infection on the penis (balanitis)
- Conditions predisposing to priapism, including sickle cell disease, multiple myeloma, polycythemia, leukemia, or thrombophilia
- History of recurrent prolonged painful erections (priapism)
- Medical advice against sexual activity, such as severe cardiovascular disease, unstable angina, recent myocardial infarction, or recent stroke
Warnings and Precautions
Talk to your doctor or pharmacist before using Bondil if you have any of the following conditions:
- Bleeding disorders — Incorrect insertion of the applicator may cause minor urethral trauma and bleeding. If you have a blood-borne disease, this could increase the risk of transmission to your sexual partner.
- History of psychiatric illness or substance use disorder — Your doctor may want to monitor you more closely.
- Transient ischemic attack (TIA) or unstable cardiovascular disease — Sexual activity places demands on the cardiovascular system, and your doctor should assess your fitness.
- Coronary artery disease, heart failure, or lung disease — Sexual stimulation may trigger cardiac or pulmonary symptoms in patients with these conditions. The American Heart Association recommends risk stratification before initiating ED therapy.
- Penile implant — The use of intraurethral alprostadil in patients with penile prostheses has not been adequately studied and may carry additional risks.
If your erection lasts 4 hours or longer, seek immediate medical attention. Priapism is a medical emergency that can cause irreversible damage to the erectile tissue if not treated promptly. Treatment may include aspiration and injection of sympathomimetic agents.
Pregnancy and Breastfeeding
If your female partner is pregnant or you suspect she may be pregnant, a condom must be used during intercourse when using Bondil. Although systemic absorption of alprostadil following intraurethral administration is minimal, the potential effects on the developing fetus have not been fully established. The use of barrier contraception is also recommended for couples planning to conceive, until the physician advises otherwise.
Driving and Operating Machinery
Bondil may cause dizziness and fainting, particularly during initial use or within one hour of administration. If you experience these symptoms, do not drive, operate heavy machinery, or engage in activities requiring alertness until the effects have subsided. The European Medicines Agency advises patients to assess their individual response before undertaking such activities.
How Does Bondil Interact with Other Drugs?
Drug interactions with Bondil can affect its efficacy and safety profile. As alprostadil acts as a vasodilator, it can potentiate or antagonize the effects of several classes of medications. The European Medicines Agency and the British National Formulary recommend careful monitoring when Bondil is used concomitantly with the following drug classes:
Major Interactions
| Drug Class | Examples | Interaction Effect | Risk Level |
|---|---|---|---|
| PDE5 Inhibitors | Sildenafil (Viagra), Tadalafil (Cialis), Vardenafil (Levitra) | Increased risk of priapism and severe hypotension due to additive vasodilatory effects | High |
| Anticoagulants & Antiplatelets | Warfarin, Heparin, Aspirin, Clopidogrel | Increased risk of urethral bleeding due to reduced clotting capacity | Moderate–High |
| Other Erectile Dysfunction Agents | Papaverine, Phentolamine, Intracavernosal alprostadil | Significantly increased risk of prolonged erection (priapism) | High |
Other Interactions
| Drug Class | Examples | Interaction Effect | Risk Level |
|---|---|---|---|
| Antihypertensives | ACE inhibitors, Beta-blockers, Calcium channel blockers, Diuretics | Enhanced blood pressure lowering effect; increased risk of hypotension and dizziness | Moderate |
| Sympathomimetics | Pseudoephedrine, Phenylephrine, Ephedrine | Reduced effectiveness of Bondil due to opposing vasoconstrictor action | Moderate |
| Vasoactive Agents | Nitrates (nitroglycerin), Alpha-blockers (tamsulosin, doxazosin) | Unpredictable blood pressure changes; risk of significant hypotension or hypertension | Moderate |
| Muscle Relaxants | Baclofen, Tizanidine, Dantrolene | Potential additive smooth muscle relaxation; theoretical risk of prolonged erection | Low |
Always inform your doctor or pharmacist about all medications you are currently taking, have recently taken, or plan to take. This includes prescription medications, over-the-counter products, herbal supplements, and vitamins. Your healthcare provider can then determine whether Bondil is safe for you and whether any dosage adjustments or additional monitoring are needed.
What Is the Correct Dosage of Bondil?
Bondil should always be used exactly as prescribed by your doctor. The dose is individually tailored based on your response to treatment. Your physician will typically begin with a test dose in the clinic to determine the optimal strength and to teach you proper administration technique.
Adults
Standard Adult Dosing
- Starting dose: 500 micrograms (mcg) per application
- Dose adjustment: If the starting dose does not produce an adequate erection, your doctor may increase the dose. Do not increase the dose on your own.
- Maximum single dose: 1000 mcg
- Maximum frequency: No more than 2 doses in any 24-hour period
- Weekly limit: No more than 7 doses in any 7-day period
Children and Adolescents
Bondil is not indicated for use in children or adolescents under 18 years of age. There are no established safety or efficacy data for this population. Erectile dysfunction treatment in younger males requires specialist evaluation and a different therapeutic approach.
Elderly Patients
There is no specific dose adjustment required for elderly patients based solely on age. However, elderly men may be more susceptible to cardiovascular side effects including hypotension and dizziness. Physicians should carefully assess cardiovascular fitness before prescribing Bondil to older patients, in accordance with the American Heart Association and EAU guidelines on sexual activity and cardiovascular risk.
How to Use the Applicator
Bondil comes in a single-use applicator system. Follow these steps carefully for optimal results:
- Allow the product to reach room temperature before use. Do not heat it artificially.
- Urinate before administration to moisten the urethra, which facilitates insertion and helps dissolve the medication.
- Open the foil pouch and let the applicator slide out. Twist off the protective cap. Do not press or pull the button at the top of the applicator.
- Hold the penis upright and gently squeeze the glans (tip) to straighten and open the urethra.
- Gently insert the applicator tube into the urethra up to the collar of the applicator. If you experience discomfort, withdraw slightly and reinsert.
- Press the button on the applicator as far as it will go and hold for 5 seconds to ensure the full dose is released.
- Gently rock the applicator from side to side, then remove it while keeping the penis upright.
- Massage the penis while holding it upright for at least 10 seconds to distribute the medication along the urethral walls. If you experience a burning sensation, continue massaging for an additional 30–60 seconds until it subsides.
Erection typically begins within 5–10 minutes of administration. Active foreplay positively enhances the erectile response.
Missed Dose
Bondil is used on an as-needed basis before sexual activity, not on a fixed schedule. There is no concept of a “missed dose.” Simply use it when needed, observing the maximum frequency limits described above.
Overdose
If you have used too much Bondil or if someone has accidentally ingested the medication, contact a healthcare provider, hospital emergency department, or poison control center immediately. Symptoms of overdose may include prolonged erection (priapism), severe hypotension, dizziness, and fainting. Priapism lasting more than 4 hours requires urgent urological intervention to prevent permanent tissue damage.
What Are the Side Effects of Bondil?
Like all medicines, Bondil can cause side effects, although not everybody gets them. Most side effects are local to the application site and tend to be mild to moderate in severity. Clinical trials published in Urology and the British Journal of Urology have demonstrated that the majority of side effects diminish with continued use as patients become more proficient with the administration technique.
- Your erection lasts longer than 4 hours (priapism)
- Your penis becomes scarred or curved
- Your testicles or scrotum become red, swollen, or painful
Very Common
Affects more than 1 in 10 users
- Burning sensation in the urethra
- Penile pain
Common
Affects 1 in 10 to 1 in 100 users
- Headache
- Dizziness
- Muscle spasms
- Low blood pressure (hypotension)
- Minor bleeding from the urethra
- Testicular pain
- Penile bruising
- Increased erection
Uncommon
Affects 1 in 100 to 1 in 1,000 users
- Fainting or feeling faint (vasovagal syncope)
- Altered sensation (increased or decreased)
- Leg vein swelling
- Leg pain
- Pelvic or perineal pain
- Increased heart rate (tachycardia)
- Vasodilation causing dizziness
- Nausea
- Skin rash, itching, or redness
- Increased sweating
- Urinary urgency and frequency
- Painful or difficult urination (dysuria)
- Blood in urine (hematuria)
- Elevated blood creatinine levels
- Priapism (prolonged erection lasting >4 hours)
- Testicular or scrotal redness, swelling, or pain; spermatocele (benign cysts)
- Penile numbness
- Uncomfortable or painful erections, or absence of erection
- Altered ejaculation
- Swollen or tight foreskin (phimosis); swelling of the glans
Rare
Affects 1 in 1,000 to 1 in 10,000 users
- Urinary tract infection
- Penile scarring or curvature (particularly with long-term use)
Very Rare
Affects fewer than 1 in 10,000 users
- Urticaria (hives)
Effects on Sexual Partners
Female sexual partners may occasionally experience vaginal itching or burning during intercourse. This is typically related to the resumption of sexual activity rather than direct drug exposure, although small amounts of alprostadil may be transferred. Using a condom is recommended if your partner is pregnant or if vaginal irritation becomes a recurring issue.
Reporting Side Effects
Reporting suspected adverse reactions after a medication has been authorized is important. It allows continued monitoring of the benefit-risk balance of the medicine. Healthcare professionals and patients are encouraged to report side effects to their national pharmacovigilance authority (e.g., the FDA MedWatch program in the United States, the Yellow Card scheme in the United Kingdom, or the EMA EudraVigilance system in Europe).
How Should You Store Bondil?
Proper storage of Bondil is essential to maintain the stability and efficacy of the alprostadil pellet. Alprostadil is a temperature-sensitive compound, and exposure to excessive heat can degrade the active ingredient, reducing its effectiveness.
- Long-term storage: Keep in a refrigerator at 2–8°C (36–46°F).
- Short-term storage: The currently used pack can be stored at room temperature (up to 30°C / 86°F) for a maximum of 14 days.
- Avoid heat exposure: Do not leave Bondil in a car, near a radiator, or in direct sunlight where temperatures may exceed 30°C.
- Expiry date: Do not use after the expiry date (EXP) printed on the carton and label. The expiry date refers to the last day of that month.
- Keep out of reach of children: Store in a location inaccessible to children.
- Disposal: Used applicators should be disposed of with normal household waste. Do not flush medications down the toilet or drain unless specifically instructed.
What Does Bondil Contain?
Bondil is formulated as a sterile, solid pellet (medicated urethral suppository) designed for intraurethral administration using a single-use applicator system.
Active Ingredient
| Ingredient | Amount per Suppository | Function |
|---|---|---|
| Alprostadil (PGE1) | 500 mcg or 1000 mcg | Vasodilator — relaxes smooth muscle and increases blood flow to the penis |
Excipient
The only inactive ingredient is macrogol (polyethylene glycol), which serves as the carrier matrix for the alprostadil pellet. Macrogol is a biocompatible, water-soluble polymer that dissolves in the residual urine within the urethra, releasing the active ingredient for mucosal absorption.
Physical Description
The pellet is a smooth, off-white to slightly yellow sterile stick, measuring 1.4 mm in diameter and 3 or 6 mm in length (depending on the strength). It is housed inside a disposable applicator packaged in an individual foil pouch. Available pack sizes include 1, 2, 6, and 10 applicators per box, though not all pack sizes may be marketed in all regions.
Frequently Asked Questions About Bondil
Bondil (alprostadil) is a prescription urethral suppository used to treat erectile dysfunction (ED) in adult men aged 18 years and older. The active ingredient, prostaglandin E1, increases blood flow to the penis by relaxing smooth muscle in the erectile tissue, producing an erection typically within 5 to 10 minutes of administration. It may also be used as a diagnostic tool for evaluating erectile function in a clinical setting.
Bondil is administered using a single-use applicator inserted into the urethra. Urinate before use to moisten the urethra, then insert the applicator tube fully into the urethra while holding the penis upright. Press the button for 5 seconds to release the pellet, then gently remove the applicator and massage the penis for at least 10 seconds. Erection typically begins within 5-10 minutes. Active foreplay can enhance the response.
Combining Bondil with phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Viagra), tadalafil (Cialis), or vardenafil (Levitra) is generally not recommended without medical supervision. The combination significantly increases the risk of priapism (prolonged erection lasting more than 4 hours) and may cause dangerous drops in blood pressure. Always consult your doctor before combining erectile dysfunction treatments.
A prolonged erection lasting 4 hours or longer (priapism) is a medical emergency. Seek immediate medical attention at a hospital emergency department. Without prompt treatment, priapism can cause permanent damage to the erectile tissue, potentially leading to permanent erectile dysfunction. Emergency treatment may include aspiration of blood from the corpora cavernosa and injection of a sympathomimetic agent such as phenylephrine.
Yes, a mild to moderate burning sensation in the urethra is the most commonly reported side effect of Bondil, occurring in more than 1 in 10 users. This is caused by the pharmacological action of alprostadil on the urethral mucosa and typically lasts only a few minutes. Massaging the penis for an additional 30-60 seconds after insertion can help reduce the burning. The sensation usually becomes less noticeable with repeated use as the urethra becomes accustomed to the medication.
Bondil should be stored in a refrigerator at 2-8°C. The current pack in use can be kept at room temperature (up to 30°C) for a maximum of 14 days. Do not leave Bondil in a car, near a heat source, or in direct sunlight. Used applicators should be disposed of with normal household waste. Always check the expiry date on the packaging before use.
References & Sources
- European Association of Urology (EAU). Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation. EAU Guidelines Office, 2024.
- American Urological Association (AUA). Guideline on the Management of Erectile Dysfunction: Diagnosis and Treatment. AUA Guideline, 2023 Update.
- Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. New England Journal of Medicine. 1997;336(1):1-7. doi:10.1056/NEJM199701023360101
- European Medicines Agency (EMA). Alprostadil Summary of Product Characteristics. EMA, 2024.
- Montague DK, Jarow JP, Broderick GA, et al. The Management of Erectile Dysfunction: An AUA Update. Journal of Urology. 2005;174(1):230-239.
- Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease. Mayo Clinic Proceedings. 2012;87(8):766-778.
- International Society for Sexual Medicine (ISSM). Guidelines on Erectile Dysfunction. ISSM, 2023.
- British National Formulary (BNF). Alprostadil. National Institute for Health and Care Excellence (NICE), 2025.
- World Health Organization (WHO). Sexual and Reproductive Health: Erectile Dysfunction Fact Sheet. WHO, 2023.
- Costabile RA, Spevak M, Fishman IJ, et al. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. Journal of Urology. 1998;160(4):1325-1328.
Medical Editorial Team
Medical Content
iMedic Medical Editorial Team — Specialists in Urology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board — Independent panel of licensed physicians
Evidence Standards
GRADE Framework — Evidence Level 1A (Systematic Reviews & RCTs)
Guidelines Followed
EAU, AUA, ISSM, EMA, FDA, BNF, WHO
Last reviewed: | Published: | Conflict of interest: None. No commercial funding.